The novel, long-acting GLP-2 analog apraglutide improves colonic permeability in short bowel syndrome with chronic intestinal failure
Background: Glucagon-like peptide-2 (GLP-2) analogs stimulate adaptation of the remaining gut of patients with short bowel syndrome and intestinal failure (SBS-IF), resulting in increased intestinal absorption. Overall, preclinical data suggest intestinal permeability may be compromised in patients with SBS, which may contribute to fluid losses. However, it remains unclear whether this can be improved by GLP-2 analog treatment.
Authors
- Joran Tóth
- Pauline Huyghe
- Francisca Joly (ORCID: https://orcid.org/0000-0002-9341-7133)
- Ricard Farré (ORCID: https://orcid.org/0000-0001-7158-171X)
- Lucas Wauters (ORCID: https://orcid.org/0000-0002-3195-4996)
- Tim Vanuytsel (ORCID: https://orcid.org/0000-0001-8728-0903)
- Palle Bekker Jeppesen (ORCID: https://orcid.org/0000-0001-9680-6938)
- Astrid Verbiest (ORCID: https://orcid.org/0000-0002-6130-7132)
- Lise De Meyere
Institutions
- Inserm (FR)
- Hôpital Beaujon (FR)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- KU Leuven (BE)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100085
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00